Latest Articlesddd
Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …
Sangamo’s Stock Price Soars Sangamo Therapeutics’ (SGMO) stock soared more than 52% in pre-market trading following …
The Market is Outperforming Today. There is important news today about Novartis; part of which we …
Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody …
The uncontrolled blowing toxic wind contaminates this country’s environment, it brings down the oversold scientifically solid …
While waiting for Mueller’s report we stopped speculating on the stocks in what we saw as …
Governor Cooper to cut ribbon on bluebird bio facility Bluebird bio (BLUE) announced today, in its …
Biogen’s (BIIB) decision to discontinue the global Phase 3 trials, ENGAGE and EMERGE which is designed …
News We Loved to Hear The First and Only Approval of a Specific Product for Postpartum …
The Week in Review #39 During the Departed Week Three Prohost Portfolio Picks Hit Their 52-Week …
Prohost Letter #429 End of the Year Decisions ~ Part 4 We picked for our portfolio …
Atossa Genetics (ATOS) announced that the FDA has issued a “Safe to Proceed” letter under their “expanded …
We love to read news about gene therapy as it is the only possibility for curing …
Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines …
The Week in Review #38 SYNOPSIS Good News and Setbacks During the Departed Week from the …
CRISPR Therapeutics' (CRSP) stock added around $8 today while reporting financial results for the fourth quarter …
We congratulate our subscribers who kept Spark Therapeutics (ONCE) in spite of the stock’s kind of paralysis for no …
Cytokinetics’ (CYTK) investigational product omecamtiv mecarbil, the firm’s potential treatment for heart failure with reduced ejection fraction, …
Keytruda and Cabometyx Are Both Winners Keytruda failed to meet co-primary endpoints in Pivotal Phase 3 …
From the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) Prostate Cancer A presentation …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
